Trial Profile

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fasudil (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Acronyms REAL
Sponsors Woolsey Pharmaceuticals

Most Recent Events

08 Apr 2025 Planned End Date changed from 1 Jan 2028 to 1 Jan 2029.
10 Jan 2025 According to a Woolsey Pharmaceuticals media release, Data from the 300 mg/day REAL cohort is expected in June 2025
12 Nov 2024 According to a Woolsey Pharmaceuticals media release, the company announced the successful completion of patient recruitment (n=31) in the high-dose (300 mg/day) cohort of the REAL study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com